BrightSpring Health Services, Inc. BTSG
Deals with insiders in the proxy filed Apr 10, 2026
Proxy, Item 404Deals between BTSG and its directors, executives, owners of more than 5% or their families: a relative on the payroll, a plane the company charters from its CEO, a director's company that buys from it. SEC rules (Item 404) make the company list every such deal over $120,000 in its proxy statement.
New this year
Compared with Apr 18, 2025
Paragraphs about a deal, a person or a relative with nothing like them in the proxy filed Apr 18, 2025.
Nothing new: every deal in this year's section was reported last year too.
No longer reported 4 paragraphs of the proxy filed Apr 18, 2025 with nothing like them this year
Monitoring Agreement“On March 5, 2019, our subsidiary, Phoenix Guarantor, Inc., entered into the Monitoring Agreement with Kohlberg Kravis Roberts & Co. L.P. (“KKR”) and Walgreens Boots Alliance, Inc. (together with KKR, the “Managers”) pursuant to which the Managers provided consulting services to us. In accordance with the terms of the Monitoring Agreement, we paid an aggregate annual advisory fee equal to 1% of the Consolidated EBITDA (as defined under the First Lien Credit Agreement) for the preceding year, which fee was split between the Managers on a pro rata basis based on KKR Stockholder’s and Walgreens Stockholder’s respective ownership of our common stock. The Managers could also charge us a customary fee for services rendered in connection with acquisitions, divestitures, or other transaction, including securing, structuring, and negotiating equity and debt financings by us. Additionally, we were required to reimburse the Managers for any out-of-pocket expenses in connection with these services. Prior to the termination of the Monitoring Agreement, we recognized $0.7 million in monitoring and advisory fees during the first fiscal quarter of 2024. As a result of the termination of the Monitoring Agreement and in accordance with the agreement, we paid $22.7 million in termination fees to the Managers. The termination fees were recognized in the first fiscal quarter of 2024.”
Read it in last year's proxyopen_in_new
Relationship with KKR Capital Markets“KKR Capital Markets LLC (“KCM”), a wholly owned subsidiary of KKR, acted as an underwriter in the initial public offering during the first fiscal quarter of 2024 and received $7.4 million in underwriting discounts and commission In connection with debt refinancing in 2024 and the Revolver upsize in 2023, we paid underwriter, arranger, and transaction fees to KCM of $3.7 million and $2.4 million, respectively.”
Read it in last year's proxyopen_in_new
Other Arrangements“We have certain agreements with our directors and officers which are described in the section entitled “Executive Compensation.””
Read it in last year's proxyopen_in_new
Other Arrangements“We have entered into indemnification agreements with our directors and executive officers. These agreements and our Bylaws require us to indemnify these individuals to the fullest extent permitted under Delaware law against liabilities that may arise by reason of their service to us, and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified. The indemnification provided under the indemnification agreements is not exclusive of any other indemnity rights. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors and executive officers, we have been informed that in the opinion of the SEC such indemnification is against public policy and is therefore unenforceable.”
Read it in last year's proxyopen_in_new
The whole section
As filed
10 paragraphs quoted as filed
Statement of Policy Regarding Transactions with Related Persons“Our Board of Directors recognizes the fact that transactions with related persons present a heightened risk of conflicts of interests and/or improper valuation (or the perception thereof). Our Board of Directors adopted a written statement of policy regarding transactions with related persons, which we refer to as our “related person transaction policy,” that is in conformity with the requirements applicable to issuers having publicly-held common stock that is listed on Nasdaq.”
Read it in the proxyopen_in_new
Statement of Policy Regarding Transactions with Related Persons“Our related person transaction policy requires that a “related person” (as defined as in paragraph (a) of Item 404 of Regulation S-K) must promptly disclose to our chief legal officer or chief accounting officer, or such other person designated by the Board of Directors, any “related person transaction” (defined as any transaction that we anticipate would be reportable by us under Item 404(a) of Regulation S-K in which we were or are to be a participant and the amount involved exceeds $120,000 and in which any related person had or will have a direct or indirect material interest) and all material facts with respect thereto. The chief legal officer or chief accounting officer, or such other person, will then promptly communicate that information to our audit committee. Subject to limited transactions deemed pre-approved, no related person transaction entered into will be executed without the approval or ratification of our audit committee.”
Read it in the proxyopen_in_new
Statement of Policy Regarding Transactions with Related Persons“The following is a summary of such related person transactions since January 1, 2025 in which the amount involved exceeded or will exceed $120,000.”
Read it in the proxyopen_in_new
Stockholders Agreement“Prior to our initial public offering, we entered into the Amended and Restated Stockholders’ Agreement, dated as of March 5, 2019, with the KKR Stockholder, an affiliate of Walgreens Boots Alliance, Inc. (the “Walgreens Stockholder”) and the other parties thereto (the “Stockholders Agreement”). As the Walgreens Stockholder no longer has an ownership interest in the Company, the Walgreens Stockholder no longer has the benefit of the Stockholders Agreement. The Stockholders Agreement grants the KKR Stockholder the right to nominate to our Board of Directors a number of designees equal to the product (rounded up or down to the nearest whole number) of (x) the total number of directors constituting the entire Board of Directors, multiplied by (y) the percentage of the issued and outstanding shares of our capital stock beneficially owned by the KKR Stockholder. As of the record date, the KKR Stockholder continues to meet its ownership requirements and has the right to designate the number of directors and director votes as specified in the Stockholders Agreement.”
Read it in the proxyopen_in_new
Registration Rights Agreement“On December 7, 2017, we entered into a registration rights agreement with the KKR Stockholder and the Walgreens Stockholder and the other parties thereto (the “registration rights agreement”). As the Walgreens Stockholder no longer has an ownership interest in the Company, the Walgreens Stockholder no longer has the benefit of the registration rights agreement. Subject to certain conditions, the registration rights agreement provides the KKR Stockholder with an unlimited number of “demand” registrations. Under the registration rights agreement, all holders of registrable securities party thereto are provided with customary “piggyback” registration rights, with certain exceptions. The registration rights agreement also provides that we will pay certain expenses of these holders relating to such registrations and indemnify them against certain liabilities which may arise under the Securities Act. Refer to “Secondary Offerings” below for additional information.”
Read it in the proxyopen_in_new
Pharmaceutical Purchase and Distribution Agreement“On December 7, 2017, PharMerica entered into the Joinder Agreement and Eighth Amendment (the “Eighth Amendment”), to the Pharmaceutical Purchase and Distribution Agreement between Walgreens Boots Alliance, Inc., (“WBA”), and certain of its affiliates, and AmerisourceBergen Drug Corporation (“ABDC”). ABDC is a global pharmaceutical distributor of pharmaceutical products and services. PharMerica, pursuant to the Eighth Amendment as a third-party beneficiary to the Pharmaceutical Purchase and Distribution Agreement, has the right to participate in certain pricing and payment related terms, subject to the terms thereof. The Pharmaceutical Purchase and Distribution Agreement was terminated in the first quarter of 2025, and PharMerica entered into a separate agreement with ABDC. For the fiscal year ended December 31, 2025, PharMerica purchased approximately $147.8 million at invoice cost, subject to certain pricing terms of the Pharmaceutical Purchase and Distribution Agreement.”
Read it in the proxyopen_in_new
WBAD - Membership Agreement“On May 30, 2018, PharMerica entered into the WBAD - Membership Agreement with Walgreens Boots Alliance Development GmbH (“WBAD”). Pursuant to the WBAD - Membership Agreement, PharMerica appointed WBAD to negotiate certain commercial and other mutually agreed upon terms for generic pharmaceutical products in accordance with guiding principles that address topics such as improvements in pricing and notification regarding switches in suppliers. The WBAD - Membership Agreement was terminated in the first fiscal quarter of 2025 in connection with PharMerica’s new agreement with ABDC. For the fiscal year ended December 31, 2025, PharMerica purchased approximately $13.1 million at invoice cost, subject to certain pricing terms of the WBAD - Membership Agreement.”
Read it in the proxyopen_in_new
Management Stockholders’ Agreement“We and the KKR Stockholder have entered into a management stockholders’ agreement (“Management Stockholders’ Agreement”), with certain of our senior executive officers and other employees who made an equity investment in us or were granted equity-based awards pursuant to the 2017 Stock Plan or otherwise held equity prior to our initial public offering.”
Read it in the proxyopen_in_new
Management Stockholders’ Agreement“The Management Stockholders’ Agreement imposes significant restrictions on transfers of shares of our common stock and equity awards held by management stockholders prior to our initial public offering. Generally, shares are nontransferable by any means at any time prior to the earlier of (x) a “Change of Control” (as defined in the Management Stockholders’ Agreement) or (y) the date on which the KKR Stockholder and its affiliates’ beneficial ownership in us is less than 10%, or the earlier of (x) or (y), the Lapse Date, except (i) prior to the Lapse Date, transfers by management stockholders who are not subject to the reporting requirements of Section 16 in amounts to be determined based on the amount of our common stock, or any warrants, rights, calls, options, or other securities exchangeable or exercisable for, or convertible into, our common stock sold in public, registered offering(s) by the KKR Stockholder and its affiliates, (ii) transfers to a “Permitted Transferee” (as defined in the Management Stockholders’ Agreement); (iii) transfers by management stockholders who are subject to the reporting requirements of Section 16 pursuant to the proper exercise of “piggyback” registration rights under the Management Stockholders’ Agreement; (iv) transfers approved by our Board of Directors in its sole discretion; or (v) transfers to us, or the KKR Stockholder or its affiliates.”
Read it in the proxyopen_in_new
Management Stockholders’ Agreement“Additionally, management stockholders who are subject to the reporting requirements of Section 16 have limited “piggyback” registration rights with respect to registered offering(s) to the extent the KKR Stockholder and its affiliates participate.”
Read it in the proxyopen_in_new
Paragraphs are compared by their words, not read by AI: one counts as new when no paragraph last year shares half of its words, or when it names a person or company last year's section did not. A deal reported again with a new amount is not new. Always check the filing. Open the proxy ↗ · Last year's proxy ↗
Sources
The related-party section (Item 404) of the latest annual proxy statement (DEF 14A), against last year's, compared by their words.
Also
CEO pay: the same proxy's pay versus performance table.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BTSG/export.csv") into a cell.